Join
Live feed
·
PRReleasevia Quantisnow
BeOne Medicines Ltd. logo

BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer

ByQuantisnow·Wall Street's wire, on your screen.
ONC· BeOne Medicines Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ONC (BeOne Medicines Ltd.) and more on Quantisnow.